1h Free Analyst Time
Global Bleeding Disorders Therapeutics Market: About this marketSpeak directly to the analyst to clarify any post sales queries you may have.
The bleeding disorders therapeutics market analysis considers sales from types of bleeding disorders therapeutics such as Hemophilia A, Hemophilia B, Von Willebrand disease, and other disorders. Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the Hemophilia A segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing demand for therapeutics without human or animal proteins will play a significant role in the Hemophilia A segment to maintain its market position. Also, our global bleeding disorders therapeutics market report looks at factors such as rising initiatives to increase awareness, recent approvals, and regulatory incentives. However, high costs of treatment, difficulties associated with early treatment, and challenges related to diagnosis and management of bleeding disorders may hamper the growth of the bleeding disorders therapeutics industry over the forecast period.
Global Bleeding Disorders Therapeutics Market: Overview
Rising initiatives to increase awareness
The awareness campaigns aids in the early detection of bleeding disorders, aiding patients to start therapy in the initial stages of the disorder. Organizations such as the National Hemophilia Foundation, von Willebrand Education Network, and World Federation of Hemophilia support and are focused on raising both awareness and research funds for bleeding disorders. This increasing awareness will lead to the expansion of the global bleeding disorders therapeutics market at a CAGR of almost 7% during the forecast period.
The emergence of gene therapy
Gene therapy is one of the most advanced and extensively researched treatment methods to treat hemophilia and von Willebrand disease. This therapy delivers stable insertion and expression of a gene, whose absence is responsible for a particular bleeding disorder. Therefore, the emergence and approval of gene therapies are expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few significant players, the global bleeding disorders therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading bleeding disorders therapeutics manufacturers, that include Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.
Also, the bleeding disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 06: PIPELINE ANALYSISPART 08: CUSTOMER LANDSCAPEPART 10: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
List of Exhibits
Executive Summary
The following companies as the key players in the global bleeding disorders therapeutics market: Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of gene therapy.”
According to the report, one of the major drivers for this market is the rising initiatives to increase awareness
Further, the report states that one of the major factors hindering the growth of this market is the high costs of treatment
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Baxter International Inc.
- Bayer AG
- CSL Ltd.
- F. Hoffmann-La Roche Ltd.
- Grifols SA
- Novo Nordisk AS
- Octapharma AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
